Castle Biosciences, Inc., a company specializing in diagnostic testing for dermatological cancers, has set its sights on providing unparalleled diagnostic and prognostic testing services. The commercial-stage diagnostics firm has made waves with its lead product, DecisionDx-Melanoma, a multi-gene expression profile test designed to pinpoint the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. However, Castle Biosciences, Inc. is not content with resting on its laurels and has continued to expand its offerings. The company now boasts a proprietary GEP test specifically tailored to predict the risk of metastasis for patients with uveal melanoma, named DecisionDx-UM test. In addition, Castle Biosciences, Inc. also offers DecisionDx-SCC, a cutting-edge test that uses a 40-gene expression profile to predict an individual patient's risk of squamous cell carcinoma metastasis for patients with one or more risk factors. And that's not all - Castle Biosciences, Inc. also has two more proprietary tests: DecisionDx DiffDx-Melanoma and myPath Melanoma, which employ a 35-gene expression profile to diagnose suspicious pigmented lesions. These tests are available through physicians and their patients, and Castle Biosciences, Inc. has been in operation since its founding in 2007. The company is headquartered in Friendswood, Texas, and is not slowing down anytime soon.
Castle Biosciences's ticker is CSTL
The company's shares trade on the NASDAQ stock exchange
They are based in Friendswood, Texas
There are 201-500 employees working at Castle Biosciences
It is castlebiosciences.com/company/about-us
Castle Biosciences is in the Healthcare sector
Castle Biosciences is in the Diagnostic Substances industry
The following five companies are Castle Biosciences's industry peers: